Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Hurdles to clinical translation of human induced pluripotent stem cells
Evgenios Neofytou, … , Larry A. Couture, Joseph C. Wu
Evgenios Neofytou, … , Larry A. Couture, Joseph C. Wu
Published July 1, 2015
Citation Information: J Clin Invest. 2015;125(7):2551-2557. https://doi.org/10.1172/JCI80575.
View: Text | PDF
Review

Hurdles to clinical translation of human induced pluripotent stem cells

  • Text
  • PDF
Abstract

Human pluripotent stem cells are known to have the capacity to renew indefinitely, being intrinsically able to differentiate into many different cell types. These characteristics have generated tremendous enthusiasm about the potential applications of these cells in regenerative medicine. However, major challenges remain with the development and testing of novel experimental stem cell therapeutics in the field. In this Review, we focus on the nature of the preclinical challenges and discuss potential solutions that could help overcome them. Furthermore, we discuss the use of allogeneic versus autologous stem cell products, including a review of their respective advantages and disadvantages, major clinical requirements, quality standards, time lines, and costs of clinical grade development.

Authors

Evgenios Neofytou, Connor Galen O’Brien, Larry A. Couture, Joseph C. Wu

×

Figure 1

Flow chart of pluripotent stem cell banking.

Options: View larger image (or click on image) Download as PowerPoint
Flow chart of pluripotent stem cell banking.
Human PSCs are ideal candid...
Human PSCs are ideal candidates for developing cell therapies from either a tissue biopsy or blood collection (i). Allogeneic and autologous stem cell banking requires establishment and expansion of the starting pluripotent material (ii). Human ESCs and iPSCs are capable of differentiating into any adult cell type (iii). Therapeutically relevant cell products must undergo preclinical studies required by the FDA prior to an IND application (iv). TSE, transmissible spongiform encephalopathy. Cells must undergo processing prior to secure cryostorage (v). The cryopreserved products may either be used immediately or be held for future use as allografts in order to regenerate damaged organs (vi).

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts